Myalept

Chemical Namemetreleptin
Dosage FormInjection (subcutaneous; sterile, white, solid, lyophilized cake of 11.3 mg metreleptin per vial to deliver 5 mg per mL when reconstituted in 2.2 mL of BWFI or WFI)
Drug ClassHormones
SystemEndocrine
CompanyAmryt Pharmaceuticals
Approval Year2014

Indication

  • Used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myalept (metreleptin) Prescribing Information.2022Amryt Pharmaceuticals DAC, Dublin, Ireland
Document TitleYearSource
The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline.2016Journal of Clinical Endocrinology & Metabolism